Hikma Strikes Deal For Celltrion’s Yuflyma

Firms Agree MENA Licensing Deal For High-Concentration Adalimumab Biosimilar

 
• By Dave Wallace

Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.

MENA Region Red Background Map
Hikma has once again expanded its MENA biosimilars portfolio • Source: Shutterstock

More from Biosimilars

More from Products